Late-stage pharmaceutical pipeline management, covering Phase 3 clinical trials through regulatory submission and pre-launch preparation, is the organizational domain with the highest simultaneous demands on CEO time and attention. Investor timelines, regulatory interactions, commercial preparation, and clinical execution all converge in the two to three years before a major approval. Without a clear delegation matrix, the CEO becomes the resolution point for every cross-functional challenge in this complex system.
A delegation matrix specifies, for each significant function and decision type in late-stage pipeline management, who makes decisions independently, who decides after notifying the CEO, who decides with CEO approval, and what requires CEO or board initiation. This level of specificity is what makes effective late-stage pipeline delegation possible.
Reading the Matrix
The matrix below uses four authority levels:
A (Acts independently): The role listed makes this decision without CEO consultation unless the decision has unusual risk or cost implications.
N (Notifies CEO): The role makes this decision but informs the CEO through the weekly or monthly reporting mechanism.
C (Consults CEO): The role consults the CEO before deciding, but the CEO’s input is advisory unless they choose to escalate.
D (CEO Decides): The CEO makes this decision, typically with analysis and recommendation from the relevant functional leader.
Clinical Development Matrix
| Decision | CMO | CCO | CFO | CEO |
|---|---|---|---|---|
| Phase 3 protocol design | A | - | - | C |
| Protocol amendment (minor) | A | - | - | N |
| Protocol amendment (major/changes primary endpoint) | C | - | - | D |
| Site selection and activation | A | - | - | - |
| Enrollment strategy within approved timeline | A | - | - | N |
| Clinical hold response strategy | C | - | C | D |
| Interim analysis review and response | A | - | - | D |
| Phase 3 futility decision | C | C | C | D |
| Phase 3 completion and data lock | A | - | - | N |
| CRO selection within budget | A | - | C | N |
| CRO contract above defined threshold | C | - | C | D |
How to use this section: The CMO should be empowered to make the vast majority of Phase 3 operational decisions independently. CEO involvement concentrates at scientific program inflection points: major protocol changes, interim analysis response, and go/no-go decisions.
Regulatory Affairs Matrix
| Decision | Head of Regulatory | CMO | CCO | CEO |
|---|---|---|---|---|
| NDA/BLA submission strategy | C | C | - | D |
| FDA briefing document preparation | A | C | - | N |
| Pre-NDA meeting request | A | C | - | N |
| Advisory committee preparation | A | C | C | N |
| Advisory committee appearance structure | C | C | - | D |
| Label negotiation strategy | C | C | C | D |
| Major label commitment acceptance | C | C | C | D |
| Post-marketing study commitment acceptance | C | C | - | D |
| Complete Response Letter (CRL) response strategy | C | C | C | D |
| FDA approval announcement | - | N | N | D |
How to use this section: Regulatory strategy decisions have material investor and commercial implications. The CEO’s involvement concentrates at strategic decision points rather than operational regulatory management.
Commercial Pre-Launch Matrix
| Decision | CCO | Head of Market Access | CMO | CEO |
|---|---|---|---|---|
| Brand strategy and positioning | D | C | C | C |
| Launch price range recommendation | C | C | C | D |
| Formulary submission strategy | C | D | - | N |
| National account contracting terms | C | D | - | N |
| Major payer contracting above defined threshold | C | C | - | D |
| Commercial investment budget by category | C | C | - | D |
| Total launch investment | C | C | C | D |
| Sales force size and structure | D | - | - | C |
| Launch date recommendation | C | C | C | D |
| Launch delay decision | C | C | C | D |
How to use this section: Commercial pre-launch decisions follow a pattern where the CCO has operational authority for strategy and execution within the CEO-approved investment and launch plan, with CEO involvement for decisions that set market precedents or have major financial implications.
Medical Affairs Pre-Launch Matrix
| Decision | CMO | Head of Medical Affairs | CCO | CEO |
|---|---|---|---|---|
| KOL engagement strategy | C | D | C | N |
| Advisory board program design | A | D | - | - |
| Publication plan | A | D | - | N |
| Disease awareness campaign strategy | C | C | C | D |
| Patient advocacy partnership strategy | C | D | - | N |
| Medical congress strategy | A | D | - | - |
| Medical education investment | A | D | - | N |
How to use this section: Medical Affairs pre-launch activities are largely delegated to the CMO and Head of Medical Affairs, with the CEO involved only in disease awareness campaigns (which have significant public profile) and overall Medical Affairs investment.
Supply Chain Readiness Matrix
| Decision | Head of Supply Chain | CMO | CCO | CFO | CEO |
|---|---|---|---|---|---|
| Manufacturing scale-up strategy | D | C | - | C | N |
| Commercial inventory target | D | - | C | C | N |
| Safety stock investment | C | - | C | D | N |
| Launch supply commitment to trade | C | - | C | C | N |
| Manufacturing capacity investment above threshold | C | - | - | C | D |
For context on how supply chain delegation in late-stage development connects to the ongoing supply chain management framework, see pharma supply chain, which provides a comprehensive supply chain delegation structure for pharma CEOs.
Using the Matrix in Practice
A delegation matrix is only useful if it is actually consulted and followed. Three practices help make the matrix functional rather than theoretical:
Onboard new leaders with the matrix: When a new CMO, CCO, or Head of Regulatory Affairs joins the organization, their onboarding should include a specific review of the delegation matrix for their function. This gives them immediate clarity on their authority and eliminates the need to learn through trial and error which decisions the CEO expects to be involved in.
Review and update annually: As the company’s stage, size, and leadership team change, the matrix should be reviewed. Thresholds that were appropriate for a company with one Phase 3 program may need adjustment for a company managing three simultaneous late-stage programs.
Use the matrix to diagnose over-centralization: If the CEO is consistently being asked to approve decisions that the matrix assigns to functional leaders, either the matrix needs adjustment or the functional leaders need coaching on using their authority. Both are legitimate responses; neither is ignoring the pattern.
According to McKinsey research on late-stage pharmaceutical pipeline management, the organizations that consistently achieve best-in-class late-stage development outcomes are those with clear accountability structures, strong functional leadership, and CEOs who engage at strategic inflection points without operational over-involvement. The matrix above is designed to create exactly this structure.
See pharma CEO delegation guide for a broader framework on how the late-stage pipeline delegation matrix connects to the full range of pharma CEO delegation responsibilities across research, commercial, and operational functions.
The CEO’s Role When the Matrix Breaks Down
No delegation matrix anticipates every situation. When a genuinely ambiguous or novel decision arises, the CEO’s role is to make a quick, clear decision about the appropriate process and then communicate it to the relevant team: this is a CEO decision, this is a functional leader decision with CEO advisory input, or this should be resolved through a cross-functional discussion without CEO involvement.
The CEO who uses ambiguity as an opportunity to stay involved in operational decisions gradually undermines the matrix. The CEO who uses ambiguity as a decision-forcing function that clarifies and extends the matrix builds an increasingly effective delegation structure over time.
Related Reading
For further context, explore Delegation Matrix for Arts Nonprofit CEOs and Delegation Matrix for Automotive CEO: Capital Projects.